Academic Journal of Science and Technology
ISSN: 2771-3032 | Vol. 13, No. 1, 2024

Clinical Application and Risk Assessment of CAR-T Cell Technology in Cancer Immunotherapy

Liangqi Li

Affiliated Middle School of Henan Normal University, No. 85 Jianshe East Road, Muye District, Xinxiang City, Henan Province, China

Abstract: As a cutting-edge personalized treatment method, CAR-T cell technology transforms patients' own T cells through genetic engineering, making them have the ability to specifically identify and kill tumor cells. The aim of this paper is to thoroughly organize the foundational principles and clinical utility of CAR-T cell technology, highlighting its recent advancements in treating both hematological and solid tumors. Through a comprehensive assessment of CAR-T cell technology's efficacy and risks, this study aims to inform clinical decision-making. Initially, the paper outlines the basic mechanisms of CAR-T cell technology, followed by an analysis of its notable therapeutic outcomes in hematological tumors. Additionally, it addresses the challenges posed by solid tumor treatment, including antigen expression complexity and tumor microenvironment impact. Emphasis is placed on the crucial role of regulatory bodies in enhancing oversight and developing risk management strategies to safeguard patient safety.

Keywords: Tumor immunotherapy; CAR-T cell technology; Clinical application; Risk management.

1. Introduction

Human understanding of tumor has expanded from a single abnormal cell proliferation to complex genetic variation, immune escape and other dimensions [1]. In this context, tumor immunotherapy breaks the limitations of traditional treatment methods such as surgery, radiotherapy and chemotherapy, and achieves a precise attack on tumor cells by activating or enhancing the body's own immune system, bringing new hope to tumor patients [2]. The essence of tumor immunotherapy revolves around harnessing the body's immune system to detect and eradicate cancer cells. CAR-T cell technology, a prominent immunotherapy advancement, has revolutionized tumor treatment through its unique mechanism and outstanding results [3]. CAR-T, short for chimeric antigen receptor T cell, represents genetically modified T lymphocytes capable of precisely recognizing and attaching to tumor cell surface antigens, thereby triggering T-cell killing activity [4]. This breakthrough offers a fresh therapeutic avenue for patients unresponsive to conventional treatments or experiencing relapse.

Building on early adoptive cell therapy (ACT), CAR-T technology has benefited from gene editing advancements, enabling more precise CAR-T cell design and enhanced efficacy [5]. Notably, CAR-T targeting specific tumor antigens like CD19 has shown impressive outcomes in treating relapsed or refractory B-cell lymphoma.

As clinical applications expand, various risks and challenges have emerged. Safety concerns such as cytokine release syndrome (CRS), neurotoxicity, and persistent immunodeficiency, alongside risks in CAR-T preparation, storage, and transport, pose significant hurdles for further development [6]. Balancing efficacy with risk to ensure patient safety is crucial in CAR-T research and application. This paper aims to consolidate the fundamental principles and clinical uses of CAR-T, emphasizing recent progress in hematological and solid tumor treatment. A thorough evaluation of CAR-T's efficacy and risks will inform clinical decisions and offer patients more effective treatment alternatives.

2. Basic Principle of CAR-T Cell Technology

CAR-T cells, or Chimeric Antigen Receptor T-Cells, are genetically engineered T lymphocytes designed to recognize and bind tumor cell surface antigens, activating their killing function [7]. The intricate preparation of CAR-T cells begins with isolating T lymphocytes from patient blood, which are vital for recognizing and attacking foreign invaders. Using gene vectors, the CAR gene is then introduced into these T cells. Following a series of cultivation and screening, a sufficient quantity of CAR-expressing T cells is generated and subsequently infused into patients to exert their anti-tumor effects.

The CAR-T cell's structure is integral to its function, comprising four key components: the extracellular antigen-binding domain, hinge region, transmembrane region, and intracellular signal region.

(1) The extracellular antigen-binding domain, typically a single-chain variable fragment (scFv) derived from a specific antigen-recognizing antibody, binds to tumor cell surface antigens.

(2) The hinge region connects the extracellular domain to the transmembrane region, providing support.

(3) The transmembrane region, often sourced from T cell surface molecules like CD3ζ or CD28, ensures stable CAR anchoring on the T cell membrane.

(4) The intracellular signal region contains signal transduction domains from CD3ζ and/or costimulatory molecules (e.g., CD28, 4-1BB), facilitating CAR-T cell action within T cells.

CAR-T cells operate through two primary mechanisms: specific tumor cell recognition and killing, and immune system activation.

(1) Upon entering the body, CAR-T cells recognize and bind to tumor cell surface antigens, initiating the CAR molecule's signal transduction pathway and activating T cells [8].

(2) Beyond direct tumor cell killing, CAR-T cells also

stimulate the immune system by interacting with tumor cells and releasing killer molecules that affect surrounding immune cells, such as macrophages and natural killer cells [9].

3. Clinical Application of CAR-T Cell Technology

3.1. Hematological tumor therapy

Hematological tumors, encompassing acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and multiple myeloma, represent the initial and most accomplished domains of CAR-T cell technology application. Notably, the utilization of CAR-T cell therapy targeting the CD19 antigen stands out prominently within this realm. This specific therapy has garnered significant attention due to its promising results in treating these hematological malignancies, marking a significant advancement in the field of cancer immunotherapy.

Table 1. Application of CD19-Targeted CAR-T Cell Therapy in Hematologic Malignancies

Tumor Type	Clinical Trial Phase	Efficacy Overview
Acute Lymphoblastic Leukemia (ALL)	Phase III	High complete remission rates, significant improvement in long-term survival, particularly for refractory or relapsed patients
Chronic Lymphocytic Leukemia (CLL)	Phase II/III	High effective remission rates, especially for patients with chemotherapy failure or relapse
Multiple Myeloma	Phase II/III	Significantly prolonged progression-free survival, improved overall survival

Table 1 demonstrates that CD19-directed CAR-T cell therapy has yielded impressive outcomes across ALL, CLL, and multiple myeloma treatments. Notably, numerous clinical trials highlight CAR-T's capacity to induce a substantial rate of complete remission in ALL patients, consequently enhancing their long-term survival rates. For CLL patients, particularly those experiencing chemotherapy failure or relapse, CAR-T cell therapy has exhibited a markedly effective remission rate. Moreover, in the context of multiple myeloma, CAR-T cell therapy has proven capable of significantly extending patients' progression-free survival while also boosting their overall survival rates.

3.2. Treatment of solid tumor

Despite CAR-T cell technology's notable advancements in hematological tumor treatment, its utilization for solid tumors encounters numerous hurdles. Solid tumors exhibit more complex antigen expression and a harsher microenvironment, resulting in diminished penetration, survival, and cytotoxicity of CAR-T cells.

Currently, CAR-T cell therapy for diverse solid tumors, including ovarian cancer and renal cell carcinoma, is undergoing clinical trials. While therapeutic efficacy requires further validation, preliminary findings are promising. Specifically, in treating certain ovarian cancer patients, CAR-T cell therapy demonstrates antitumor activity and extends patient survival.

Table 2. Exploration of CAR-T Cell Therapy in Solid Tumors

Tumor Type	Clinical Trial Phase	Preliminary Efficacy Overview
Ovarian Cancer	Phase I/II	Demonstrated anti-tumor activity, prolonged survival
Renal Cell Carcinoma	Phase I/II	Tumor reduction observed in some patients, further efficacy validation needed
Tumor Type	Clinical Trial Phase	Preliminary Efficacy Overview

As depicted in Table 2, clinical trials are currently assessing the potential of CAR-T cell therapy for treating solid tumors, including ovarian cancer and renal cell carcinoma, with early signs of effectiveness noted. Although these initial findings require additional confirmation, they offer invaluable understanding and expertise in utilizing CAR-T cell technology to tackle the complexities of solid tumors. The continuing investigation highlights the promising prospects of CAR-T therapy in broadening its applicability from hematological malignancies to solid tumors, thus setting the stage for future progress and enhancements in therapeutic approaches.

4. Risk Assessment of CAR-T Cell Technology

4.1. Main adverse reactions

The main adverse reactions associated with CAR-T cell therapy include cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). CRS is characterized by a systemic inflammatory cascade, while ICANS exhibits neurotoxic impacts on the central and/or peripheral nervous systems. Both reactions are mechanistically tied to the release of cytokines subsequent to CAR-T cell activation, which may provoke a systemic inflammatory response and harm the nervous system. Managing these reactions poses considerable challenges in the care of patients undergoing CAR-T cell therapy.

Table 3. Major Adverse Reactions of CAR-T Cell Therapy

Adverse Reaction Type	Description	Incidence Rate
Cytokine Release Syndrome (CRS)	A systemic inflammatory response caused by the massive release of cytokines following CAR-T cell activation, which may include fever, hypotension, dyspnea, etc.	≥ Grade 3 CRS: 10%-30%
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)	Involves the central nervous system, with symptoms including altered mental status, attention deficit, headache, tremor, behavioral changes, seizures, etc.	≥ Grade 3 ICANS: 5%-26%

Table 3 reveals that CRS and ICANS are the most common and severe adverse reactions linked to CAR-T cell therapy. Various factors, such as the CAR-T cell dose administered, tumor burden, and patient's immune status, significantly impact the incidence and severity of these reactions. This complex interplay of factors emphasizes the need for tailored treatment strategies and rigorous monitoring to reduce risks and enhance the safety of CAR-T cell therapy.

4.2. Long-term security issues

In addition to the short-term adverse reactions mentioned above, CAR-T cell therapy also has some long-term safety problems. For example, CAR-T cells may cause persistent immunosuppression or immune disorder, increasing the risk of infection in patients. In addition, CAR-T cell therapy may interact with patients' basic diseases or combined medication, leading to new complications. More seriously, studies have shown that CAR-T cell therapy may increase the risk of secondary malignant tumor. CAR-T cell therapy targeting BCMA or CD19 has been reported to be related to the occurrence of T cell malignant tumor. Although this risk is relatively low, it still needs to be highly valued.

4.3. Regulatory measures and risk management

Considering the risks associated with CAR-T cell therapy, regulatory bodies have implemented numerous measures to safeguard patient safety. An example is the US Food and Drug Administration (FDA), which mandates rigorous safety evaluations for CAR-T cell therapy products and ongoing monitoring of adverse events post-marketing. At the same time, FDA also requires that the potential risks and adverse reactions be clearly marked in the product specifications, so that doctors and patients can fully understand and make informed decisions. In China, National Medical Products Administration (NMPA) has also strengthened the supervision of CAR-T cell therapy products. NMPA also organizes experts to conduct in-depth research and discussion on related risks in order to formulate more effective risk management strategies.

4.4. Risk management strategy

To mitigate the risks associated with CAR-T cell therapy and enhance patient safety, researchers and clinicians have implemented various risk management strategies. These include rigorous adherence to quality standards and operational protocols during CAR-T cell preparation, conducting thorough patient evaluations and screenings prior to infusion, and closely monitoring patients' vital signs and adverse reactions post-infusion, with prompt interventions as necessary. Furthermore, researchers are continually innovating in CAR-T cell design and production to boost efficacy and minimize adverse effects. Examples include refining CAR molecule structures to decrease CRS and ICANS incidences, and incorporating novel costimulatory molecules to augment CAR-T cell persistence and antitumor activity.

5. Conclusions

CAR-T cell technology, a pioneering domain in tumor immunotherapy, harbors substantial clinical application promise. It has demonstrated impressive outcomes in the management of hematological tumors. Nevertheless, its application in treating solid tumors encounters numerous hurdles, such as intricate antigen expression patterns and the tumor microenvironment's harsh conditions. Researchers are diligently exploring novel approaches to enhance CAR-T cell therapy's efficacy against solid tumors.

Accompanying CAR-T cell technology's benefits are a spectrum of risks, spanning short-term adverse reactions like cytokine release syndrome and immune effector cell-related neurotoxicity syndrome, to long-term safety concerns encompassing immunosuppression, immune dysregulation, and secondary malignancies. To safeguard patient safety, regulatory bodies have implemented stringent oversight measures and mandated the development of robust risk management strategies by researchers and clinicians.

As research progresses, CAR-T cell technology is poised to assume a more pivotal role in tumor treatment, offering hope to a greater number of patients. Continued vigilance regarding its safety and efficacy, along with ongoing refinement of treatment protocols, remains paramount.

References

[1] Liu S, Zhao Y, Gao Y, et al. Targeting metabolism to improve CAR-T cells therapeutic efficacy[J]. Chinese Medical Journal, 2024, 137(8):909-920.

[2] Li H, Yang X, Wang Z, et al. A Near-Infrared-II Fluorescent Nanocatalyst for Enhanced CAR T Cell Therapy against Solid Tumor by Immune Reprogramming[J]. ACS Nano, 2023, 17(12):11749-11763.

[3] Lu Wenbin, Gong Xuechao, Jin Jianhua, et al. Research progress and optimization strategy of TCR/CAR modified T cells in tumor immunotherapy [J]. Journal of Immunology, 2018, 34(02):163-173.

[4] Dimitri A, Herbst F, Fraietta J A. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing[J]. Molecular Cancer, 2022, 21(1):1-13.

[5] Li Chunhui, Li Chunrui. Application of CAR-T cell therapy in autoimmune diseases [J]. Journal of Internal Medicine, 2023, 29(5):363-369.

[6] Zhang Guizhen, Yu Zujiang, Han Shuangyin. Research progress of B7-H3 targeting CAR-T cells in solid tumor immunotherapy [J]. China Journal of Immunology, 2022, 38(21):2650-2655.

[7] Zhang Z, Yang N, Xu L, et al. Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy[J]. Cancer Immunology, Immunotherapy, 2024, 73(9):1-14.

[8] Vagnozzi R J, Mckinsey T A. T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR[J]. Cell stem cell, 2022, 29(3):352-354.

[9] Grosser R, Cherkassky L, Chintala N, et al. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors[J]. Cancer Cell, 2019, 36(5):471-482.